clinical trial · NCT01762839
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
Melinta Therapeutics, Inc.·phase1·completed·n = 150
HealthySingle-Dose IV Oritavancin DiphosphatePlaceboMoxifloxacin
brief summary
The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
started
Dec 27, 2012
primary completion
Jan 1, 2013
completion
Feb 11, 2013
last updated
Feb 1, 2024
detailed description
This study was a single-center, double-blind, randomized, placebo-controlled, parallel-design study with an open-label, positive-control moxifloxacin arm to evaluate the effect of supratherapeutic dose of oritavancin on the QT and QT corrected for pulse rate (QTc) intervals.
official title
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol